COVID-19 is a contagious infectious disease caused by SARS-CoV-2. Clinical manifestations range from asymptomatic infection to severe pneumonia, respiratory failure, and multi-organ complications.
A systematic review and meta-analysis found high infection rates with teclistamab in relapsed/refractory multiple myeloma. Five studies showed pooled infection rates of 56.5% for any grade and 27.6% for grade 3 or higher.
The FDA pulled back publication of several studies on COVID-19 and shingles vaccines. The blocked studies involved millions of patient records, and two COVID-19 papers were withdrawn in October 2025.
FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.
The FDA reversed its refusal to review Moderna’s mRNA flu vaccine application and accepted a revised filing with split age cohorts and a post-market study for adults over 65. The reversal came amid broader vaccine regulatory uncertainty and industry concern about unpredictable review timelines.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
A federal judge froze appointments to the CDC’s ACIP, halted its votes, and paused recent HHS vaccine policy changes. The ruling leaves several FDA-approved vaccines pending review.
India has eased Press Note 3 FDI rules with a beneficial ownership test, 10% safe harbour for non-controlling LBC investments, and 60-day fast-track approvals in seven manufacturing sectors. The revised norms aim to clear 600 pending applications and boost gross FDI to $90 billion in FY26.
GeoVax is advancing Gedeptin toward a Phase 2 trial in head and neck cancer and has secured an exclusive license from Emory University for Gedeptin-ICI combination technology. The therapy has Orphan Drug Designation for oral and pharyngeal cancers.
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
BioNTech enters May with first-quarter earnings due May 5 and a May 15 shareholder vote on a capital increase. The company is pushing its oncology pipeline as COVID-19 vaccine sales decline.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597876 |
SMAtteo COvid19 REgistry (SMACORE) |
RECRUITING | |
| NCT07560059 |
Acute Metabolic Outcomes in Diabetic Patients Hospitalized for COVID-19 (DMD-COV) |
COMPLETED | |
| NCT07552779 |
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir |
RECRUITING | PHASE1 |
| NCT07536308 |
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults |
RECRUITING | PHASE1 |
| NCT07527130 |
C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome |
NOT_YET_RECRUITING | |
| NCT07516977 |
Noseguard for Prevention of Respiratory Infections in Real-World Use |
NOT_YET_RECRUITING | NA |
| NCT07501208 |
Dendritic Cell Vaccine to Prevent COVID-19 |
WITHDRAWN | PHASE1 |
| NCT07490314 |
Blood Product Supply |
COMPLETED | |
| NCT07466524 |
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study |
COMPLETED | |
| NCT07436494 |
Coronavirus Anxiety in Patients Using Biologic vs Conventional DMARDs |
COMPLETED |
